|
1) Rheault MN, Kren SM, Thielen BK, et al. Mouse model of X-linked Alport syndrome. J Am Soc Nephrol. 2004; 15: 1466-74
|
|
|
|
2) Cosgrove D, Meehan DT, Grunkemeyer JA, et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev. 1996; 10: 2981-92
|
|
|
|
|
|
3) Miner JH, Sanes JR. Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol. 1996; 135: 1403-13
|
|
|
|
|
|
4) Gross O, Beirowski B, Koepke ML, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 2003; 63: 438-46
|
|
|
|
|
|
5) Gross O, Schulze-Lohoff E, Koepke ML, et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant. 2004; 19: 1716-23
|
|
|
|
|
|
6) Gross O, Koepke ML, Beirowski B, et al. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int. 2005; 68: 456-63
|
|
|
|
|
|
7) Ninichuk V, Gross O, Reichel C, et al. Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol. 2005; 16: 977-85
|
|
|
|
|
|
8) Koepke ML, Weber M, Schulze-Lohoff E, et al. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant. 2007; 22: 1062-9
|
|
|
|
|
|
9) Chen D, Jefferson B, Harvey SJ, et al. Cyclosporine a slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): results from a canine model. J Am Soc Nephrol. 2003; 14: 690-8
|
|
|
|
|
|
10) Prodromidi EI, Poulsom R, Jeffery R, et al. Bone marrow transplantation rescues Alport mice. Stem Cells. 2006; 24: 2448-55
|
|
|
|
|
|
11) Sugimoto H, Mundel TM, Sund M, et al. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A. 2006; 103: 7321-6
|
|
|
|
|
|
12) Greer KA, Higgins MA, Cox ML, et al. Gene expression analysis in a canine model of X-linked Alport syndrome. Mamm Genome. 2006; 17: 976-90
|
|
|
|
|
|
13) Callís L, Vila A, Carrera M, et al. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int. 1999; 55: 1051-6
|
|
|
|
|
|
14) Charbit M, Gubler MC, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. 2007; 22: 57-63
|
|
|
|
|
|
15) Floege J, Kunter U, Weber M, et al. Bone marrow transplantation rescues Alport mice. Nephrol Dial Transplant. 2006; 21: 2721-3
|
|
|
|
|
|
16) Katayama K, Kawano M, Naito I, et al. Irradiation prolongs survival of Alport mice. J Am Soc Nephrol. 2008; 19: 1692-700
|
|
|
|
|
|
17) Ninichuk V, Gross O, Segerer S, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int. 2006; 70: 121-9
|
|
|
|
|
|
18) Gross O, Borza DB, Anders HJ, et al. Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrol Dial Transplant. 2009; 24: 731-4
|
|
|
|
|
|
19) Molteni A, Moulder JE, Cohen EP, et al. Prevention of radiation-induced nephropathy and fibrosis in a model of bone marrow transplant by an angiotensin II receptor blocker. Exp Biol Med (Maywood). 2001; 226: 1016-23
|
|
|
|
|
|
20) Moulder JE, Fish BL, Regner KR, et al. Retinoic acid exacerbates experimental radiation nephropathy. Radiat Res. 2002; 157: 199-203
|
|
|
|
|
|
21) Guo JK, Schedl A, Krause DS. Bone marrow transplantation can attenuate the progression of mesangial sclerosis. Stem Cells. 2006; 24: 406- 15
|
|
|
|
|
|
22) Guo JK, Ardito TA, Kashgarian M, et al. Prevention of mesangial sclerosis by bone marrow transplantation. Kidney Int. 2006; 70: 910-3
|
|
|
|
|
|
23) Kruse JJ, te Poele JA, Velds A, et al. Identification of differentially expressed genes in mouse kidney after irradiation using microarray analysis. Radiat Res. 2004; 161: 28-38
|
|
|
|
|
|
24) Abrahamson DR, Hudson BG, Stroganova L, et al. Cellular origin of type IV collagen networks in developing glomeruli. J Am Soc Nephrol. 2009; 20: 1471-9
|
|
|
|
|
|
25) Andrews KL, Mudd JL, Li C, et al. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol. 2002; 160: 721-30
|
|
|
|
|
|
26) Kang JS, Wang XP, Miner JH, et al. Loss of alpha3/alpha4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to alpha5alpha6(IV) collagen associated with longer renal survival in Col4a3-/- Alport mice. J Am Soc Nephrol. 2006; 17: 1962-9
|
|
|
|
|